Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2022 1
2023 1
2024 2
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Jongs N, Mathieu C, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Brinker M, Scheerer MF, Russell J, Schloemer P, McGill JB; FINE-ONE Investigators. Heerspink HJL, et al. N Engl J Med. 2026 Mar 5;394(10):947-957. doi: 10.1056/NEJMoa2512854. N Engl J Med. 2026. PMID: 41780000 Clinical Trial.
BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diab …
BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular …
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. Among authors: mueller k. Circulation. 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATIONAHA.124.072011. Epub 2024 Sep 29. Circulation. 2025. PMID: 39342512 Free PMC article. Clinical Trial.
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. RESULTS: Baseline LVEF data were available for 5993 of the 6001 participants in FINEARTS-HF. ...CONCLUSIONS: In patients with HF with mildly reduced or preserve …
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. RESULTS: Baseline LV …
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW; VICTORIA and VICTOR Study Groups. Zannad F, et al. Lancet. 2025 Sep 27;406(10510):1351-1362. doi: 10.1016/S0140-6736(25)01682-4. Epub 2025 Aug 30. Lancet. 2025. PMID: 40897188 Free article. Clinical Trial.
The primary endpoint was a composite endpoint of cardiovascular death or hospitalisation for heart failure (also assessed individually). This study is registered with PROSPERO, CRD420251065636. ...INTERPRETATION: Vericiguat reduced the risk of hospitalisation for heart fai …
The primary endpoint was a composite endpoint of cardiovascular death or hospitalisation for heart failure (also assessed individuall …
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators. Neuen BL, et al. Among authors: mueller k. JAMA. 2026 Jun 5:e269923. doi: 10.1001/jama.2026.9923. Online ahead of print. JAMA. 2026. PMID: 42246414 Free article.
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.
Pabon MA, Vardeny O, Vaduganathan M, Desai AS, Claggett BL, Kulac IJ, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Saldarriaga CI, Petrie MC, Merkely B, Borentain M, Mueller K, Viswanathan P, Amarante F, Morris A, McMurray JJV, Solomon SD. Pabon MA, et al. Among authors: mueller k. JAMA Cardiol. 2025 Jul 1;10(7):740-745. doi: 10.1001/jamacardio.2025.1101. JAMA Cardiol. 2025. PMID: 40397470 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular (CV) death and total (first and recurrent) worsening HF events. RESULTS: Of the 6001 participants (mean [SD] age, 72 [9.7], years; 3269 male [55%]), 273 (5%) had a prior LVEF less than 40 …
MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular (CV) death and total (first and recurrent) wors …
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Pieske B, et al. Among authors: mueller k. Eur Heart J. 2017 Apr 14;38(15):1119-1127. doi: 10.1093/eurheartj/ehw593. Eur Heart J. 2017. PMID: 28369340 Free PMC article. Clinical Trial.
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.
Chimura M, Petrie MC, Schou M, Martinez FA, Henderson AD, Claggett BL, Desai AS, Kolkhof P, Viswanathan P, Lage A, Lam CSP, Senni M, Shah SJ, Rohwedder K, Mueller K, Voors AA, Zannad F, Pitt B, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Chimura M, et al. Among authors: mueller k. Circ Heart Fail. 2024 Nov;17(11):e012437. doi: 10.1161/CIRCHEARTFAILURE.124.012437. Epub 2024 Sep 29. Circ Heart Fail. 2024. PMID: 39342655 Free PMC article. Clinical Trial.
FINEARTS-HF evaluated the impact of age on the efficacy of finerenone with respect to the primary composite outcome of cardiovascular death and total (first and recurrent) heart failure events, including heart failure hospitalization or urgent heart failure event, along wi …
FINEARTS-HF evaluated the impact of age on the efficacy of finerenone with respect to the primary composite outcome of cardiovascular …
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV. Chimura M, et al. Among authors: mueller k. JAMA Cardiol. 2025 Jan 1;10(1):59-70. doi: 10.1001/jamacardio.2024.4613. JAMA Cardiol. 2025. PMID: 39550721 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events (unplanned HF hospitalizations or urgent HF visits). ...
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events (un …
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD. Lu H, et al. Among authors: mueller k. JACC Heart Fail. 2025 Oct;13(10):102590. doi: 10.1016/j.jchf.2025.102590. Epub 2025 Aug 25. JACC Heart Fail. 2025. PMID: 40857999 Free article. Clinical Trial.
Key variables including NT-proBNP, eGFR, NYHA functional class, KCCQ-TSS, and diuretic dosing (expressed as furosemide equivalents) were serially assessed until the occurrence of cardiovascular death, first HF event, or the end of the follow-up period. Each variable was pl …
Key variables including NT-proBNP, eGFR, NYHA functional class, KCCQ-TSS, and diuretic dosing (expressed as furosemide equivalents) were ser …
Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.
Pabon MA, Ostrominski JW, Wang X, Claggett BL, Lo KB, Filippatos G, Desai AS, Jhund PS, Henderson A, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Fonseca C, Goncalvesova E, Katova T, Nodari S, Saldarriaga CI, Sharma K, Vardeny O, Zieroth S, Goland S, Rossing P, Anker SD, Pitt B, Agarwal R, Hofmeister L, Brinker M, Scalise A, Mueller K, McMurray JJV, Solomon SD, Vaduganathan M. Pabon MA, et al. Among authors: mueller k. Eur Heart J. 2026 Mar 26:ehag162. doi: 10.1093/eurheartj/ehag162. Online ahead of print. Eur Heart J. 2026. PMID: 41884984 Free article.
The risk of first HF hospitalization, cardiovascular death, major adverse cardiovascular events, kidney composite outcome, and all-cause death, was compared between men and women using adjusted Cox regression models. ...Women were more likely to have Stage 4 CKM syn …
The risk of first HF hospitalization, cardiovascular death, major adverse cardiovascular events, kidney composite outcome, and …
19 results